XXXX prophylaxis conversion in nonsurgical inpatients.

@entity1 @entity1211 @entity548
OBJECTIVE: To provide @entity1211 ( @entity1211 ) prophylaxis according to national consensus guidelines while minimizing associated medication costs. METHODS: @entity1 admitted to our institution who were receiving @entity1211 prophylaxis with the low-molecular-weight heparin (LMWH) enoxaparin were identified and evaluated for potential conversion to low-dose unfractionated heparin (LDUH). @entity1 admitted for general medical conditions were targeted for a potential conversion. Factors that excluded @entity1 from conversion were any surgical intervention or evidence of @entity548 . For all eligible @entity1 , the treating physician was contacted through written recommendations in an effort to achieve conversion to an LDUH regimen. RESULTS: Throughout a 10-month period, 463 @entity1 were identified as receiving enoxaparin for @entity1211 prophylaxis. Of these, 112 (24%) were candidates for an LDUH regimen. A total of 88 pharmacy recommendations were provided, of which 59 (67%) were accepted. This conversion program resulted in the avoidance of 250 days of enoxaparin prophylaxis and 8495 US dollars of associated medication costs. CONCLUSIONS: Clinical pharmacy programs directed at converting @entity1 from a more costly LMWH regimen for @entity1211 prophylaxis to an LDUH regimen can significantly reduce medication costs while adhering to consensus guidelines.
